Journey Medical (DERM) Aandelenoverzicht
Journey Medical Corporation, een farmaceutisch bedrijf dat zich richt op de ontwikkeling en commercialisering van farmaceutische producten voor de behandeling van dermatologische aandoeningen in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 6/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
DERM Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Journey Medical Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$5.99 |
| 52 Week Hoogtepunt | US$9.56 |
| 52 Week Laag | US$4.31 |
| Bèta | 1.04 |
| 1 maand verandering | 13.88% |
| 3 maanden verandering | -31.23% |
| 1 Jaar Verandering | -23.89% |
| 3 jaar verandering | 401.26% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -36.95% |
Recent nieuws en updates
DERM: Expanded Access And Execution Progress Will Support Future Upside
Narrative Update: Journey Medical Analyst Price Target Shift Analysts have lifted their price target on Journey Medical by $1 to $13.25, citing updated research that supports a higher valuation for the shares. Analyst Commentary Analysts highlighting the move to a US$13.25 price target are framing it as a recalibration based on refreshed research rather than a wholesale shift in the story.DERM: At The Market Liquidity And Margin Progress Will Support Future Upside
Analysts have raised their price target on Journey Medical by $1 to $13.25, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E to support the new view. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$13.25 price target as better aligned with their updated fair value work, suggesting the prior target did not fully reflect their assumptions on earnings power and risk.
Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology treatments, with Emrosi as its flagship oral therapy for inflammatory rosacea lesions. What are the underlying business or industry changes driving this perspective?Recent updates
DERM: Expanded Access And Execution Progress Will Support Future Upside
Narrative Update: Journey Medical Analyst Price Target Shift Analysts have lifted their price target on Journey Medical by $1 to $13.25, citing updated research that supports a higher valuation for the shares. Analyst Commentary Analysts highlighting the move to a US$13.25 price target are framing it as a recalibration based on refreshed research rather than a wholesale shift in the story.DERM: At The Market Liquidity And Margin Progress Will Support Future Upside
Analysts have raised their price target on Journey Medical by $1 to $13.25, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E to support the new view. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$13.25 price target as better aligned with their updated fair value work, suggesting the prior target did not fully reflect their assumptions on earnings power and risk.Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology treatments, with Emrosi as its flagship oral therapy for inflammatory rosacea lesions. What are the underlying business or industry changes driving this perspective?DERM: At The Market Offering And Margin Progress Will Drive Future Upside
Analysts have adjusted their price target for Journey Medical to $13.25 from $13.50, citing updated views on revenue growth, profit margins, and the stock's future P/E multiple as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as reflecting confidence that recent revenue trends and cost controls can support the revised P/E assumption used in their models.
Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology products, including Emrosi for rosacea, in the U.S. market. What are the underlying business or industry changes driving this perspective?DERM: At The Market Equity Offering Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Journey Medical filed a follow-on equity offering for its common stock, signaling plans to raise additional capital through the equity market (Key Developments).DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E for the company. What's in the News Journey Medical filed a follow on equity offering for its common stock as an at the market offering, giving the company the option to issue new shares into the market over time (Key Developments).DERM: Phase 1 Rosacea Microbiome Safety Will Drive Future Upside
Analysts have maintained their price target on Journey Medical at US$13.50, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions supporting this stable view. What's in the News Journey Medical filed a follow-on equity offering for its common stock as an at-the-market offering, indicating potential future issuance of additional shares (Key Developments).DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside
Analysts have reaffirmed their price target on Journey Medical at US$13.50, citing unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their view steady. What's in the News Journey Medical filed a follow-on equity offering for its common stock, structured as an at-the-market offering.Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...DERM: Phase 3 Rosacea Efficacy And Microbiome Safety Will Drive Upside
Analysts have maintained their price target for Journey Medical at US$13.50. This steady view reflects unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E.DERM: Phase 3 Rosacea Data And Microbiome Safety Will Support Further Upside
Analysts have modestly reiterated their outlook on Journey Medical, maintaining a price target of $13.50 per share as slight tweaks to the discount rate, revenue growth assumptions, profit margin, and future P E estimates leave their valuation framework effectively unchanged. What's in the News Phase 1 trial results for DFD-29, marketed as Emrosi, showed no detectable impact on skin, gastrointestinal, or vaginal microflora over 16 weeks and confirmed the therapy was well tolerated in healthy adults, supporting its use in moderate to severe rosacea (Key Developments).DERM: Phase 3 Rosacea Efficacy And Safety Will Likely Support Further Upside
Analysts have modestly reiterated their confidence in Journey Medical, maintaining their price target at 13.50 dollars. Unchanged near term revenue growth, profitability expectations, and valuation multiples continue to support the current fair value outlook.DERM: Recent Trial Success Will Likely Drive Shares Toward Upside Potential
Analysts have revised their price target for Journey Medical, maintaining it at $13.50 per share. Updates to projected profit margin and future valuation metrics prompted a reassessment of the company's growth outlook.DERM: Improved Margins and Clinical Results Are Expected to Drive Shares Higher
Analysts have raised their price target for Journey Medical from $11.80 to $13.50. They cite improved profit margin expectations despite slightly adjusted forecasts for revenue growth and discount rates.US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results
NasdaqCM:DERM 1 Year Share Price vs Fair Value Explore Journey Medical's Fair Values from the Community and select...Emrosi Launch Will Expand Rosacea Treatment Options
Journey Medical’s sharply improved net profit margin and lower future P/E ratio signal enhanced profitability and valuation appeal, driving the consensus analyst price target up from $10.50 to $11.50. What's in the News Pharmacy benefit coverage for Emrosi™ increased to 65% of US commercial lives, up from 29% in May.Is Journey Medical (NASDAQ:DERM) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Journey Medical (NASDAQ:DERM) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Emrosi Launch Will Expand Rosacea Treatment Options
Emrosi's launch and favorable Phase III results are expected to boost revenue growth and enhance net margins through existing operations.A Piece Of The Puzzle Missing From Journey Medical Corporation's (NASDAQ:DERM) 26% Share Price Climb
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Journey Medical (NASDAQ:DERM) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Market Cool On Journey Medical Corporation's (NASDAQ:DERM) Revenues Pushing Shares 26% Lower
Unfortunately for some shareholders, the Journey Medical Corporation ( NASDAQ:DERM ) share price has dived 26% in the...Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Journey Medical Corporation ( NASDAQ:DERM ) shares have had a really impressive month, gaining 31% after a shaky period...Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
To the annoyance of some shareholders, Journey Medical Corporation ( NASDAQ:DERM ) shares are down a considerable 31...Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Journey Medical Corporation ( NASDAQ:DERM ) shares have retraced a considerable 33% in the last month, reversing a fair...Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Rendement voor aandeelhouders
| DERM | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -2.9% | 3.6% | 1.3% |
| 1Y | -23.9% | 43.9% | 27.7% |
Rendement versus industrie: DERM presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 43.9 % opleverde.
Rendement versus markt: DERM presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 27.7 % opleverde.
Prijsvolatiliteit
| DERM volatility | |
|---|---|
| DERM Average Weekly Movement | 12.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: De aandelenkoers van DERM is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van DERM is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2014 | 58 | Claude Maraoui | journeymedicalcorp.com |
Journey Medical Corporation, een farmaceutisch bedrijf dat zich toelegt op de ontwikkeling en commercialisering van farmaceutische producten voor de behandeling van dermatologische aandoeningen in de Verenigde Staten. Tot de producten die het bedrijf op de markt brengt behoren Qbrexza, een doekje met medicinale werking voor de behandeling van primaire okselhyperhidrose; Accutane, een oraal isotretinoïnegeneesmiddel voor de behandeling van ernstige recalcitrante nodulaire acne; en Amzeeq, een topische formulering van minocycline voor de behandeling van inflammatoire laesies van niet-nodulaire matige tot ernstige acne vulgaris. Het biedt ook Zilxi, een topische behandeling met minocycline voor inflammatoire laesies van rosacea; Emrosi voor de behandeling van inflammatoire laesies van rosacea; Exelderm crème en oplossing voor de behandeling van schimmelinfecties van de huid; en Targadox, een oraal geneesmiddel op basis van doxycycline voor aanvullende behandeling van ernstige acne, evenals Luxamend, een emulsie op waterbasis die is samengesteld om een vochtige helende omgeving te bieden voor oppervlakkige wonden; kleine snij- of schaafwonden; huidzweren; donorplaatsen; eerste- en tweedegraads brandwonden, inclusief zonnebrand; en stralingsdermatitis.
Journey Medical Corporation Samenvatting
| DERM fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$168.51m |
| Inkomsten(TTM) | -US$9.59m |
| Inkomsten(TTM) | US$64.68m |
Is DERM overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| DERM resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$64.68m |
| Kosten van inkomsten | US$22.35m |
| Brutowinst | US$42.33m |
| Overige uitgaven | US$51.92m |
| Inkomsten | -US$9.59m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.35 |
| Brutomarge | 65.44% |
| Nettowinstmarge | -14.82% |
| Schuld/Eigen Vermogen Verhouding | 82.3% |
Hoe presteerde DERM op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/27 19:40 |
| Aandelenkoers aan het einde van de dag | 2026/05/27 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Journey Medical Corporation wordt gevolgd door 5 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Scott Henry | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |